EVFM Evofem Biosciences


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The Special Meeting was originally convened and adjourned without conducting any business on December 8, 2021. The Special Meeting was then reconvened on December 15, 2021 and held in the 6th Floor Boardroom in the Company’s principal executive office located at 12400 High Bluff Drive, Suite 600, San Diego, California 92130 and commenced at 8:00 am Pacific Standard Time. Of the Company’s 163,144,964 shares of common stock issued and outstanding and eligible to vote as of the record date of November 5, 2021, a quorum of 100,662,182 shares, or approximately 61.70% of the eligible shares, was (i) present in person or represented by proxy at the Special Meeting and (ii) voted as set forth below on the following proposal. This proposal is further described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 9, 2021 (the “Proxy Statement”).

Proposal 1

Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 300,000,000 shares to 500,000,000 shares.

Votes ForVotes AgainstVotes AbstainedBroker Non-Vote

The disclosures in